Author: Sarah VanVickle Chaves, Director of IVD and Scientific Writing Services, Ph.D. Molecular and Cellular Biology
The Performance Evaluation Report (PER) is one of the most critical technical documents required for in vitro diagnostic (IVD) medical devices under the European Union In Vitro Diagnostic Medical Device Regulation (EU) 2017/746 (IVDR). It serves as the comprehensive evidence package demonstrating that an IVD performs as intended throughout its lifecycle by integrating scientific validity, analytical performance, and clinical performance data.
For manufacturers seeking CE marking or maintaining compliance under the IVDR, developing a robust PER is essential. A well-prepared PER not only satisfies regulatory requirements but also provides confidence to notified bodies, healthcare professionals, and patients that the device is safe, effective, and supported by current scientific evidence.
This article explains what a Performance Evaluation Report is, why it is required, how it is developed, and best practices for maintaining compliance.
What Is a Performance Evaluation Report (PER)?
A Performance Evaluation Report is a comprehensive technical document that summarizes all evidence supporting the performance of an IVD medical device.
Unlike a clinical evaluation under the Medical Device Regulation (MDR), the IVDR requires manufacturers to demonstrate three distinct types of evidence:
- Scientific validity
- Analytical performance
- Clinical performance
The PER integrates these evidence streams into a single report that demonstrates the device achieves its intended purpose while maintaining acceptable benefit-risk throughout its lifecycle.
The report also documents:
- Available scientific literature
- Clinical studies
- Analytical validation studies
- Published guidelines
- State-of-the-art medicine
- Post-market evidence
The PER forms part of the Technical Documentation reviewed by the Notified Body during conformity assessment.
What Is the Purpose of a PER?
The PER demonstrates that an IVD:
- Measures the intended analyte accurately
- Produces reliable and reproducible results
- Supports the intended clinical use
- Provides clinically meaningful information
- Continues to perform throughout its commercial lifecycle
Ultimately, the PER answers three key regulatory questions:
- Is the biomarker scientifically associated with the disease or condition?
- Does the assay accurately detect or measure the analyte?
- Does the test improve or support clinical decision-making?
In practical terms, the CER is where the manufacturer connects the dots between clinical data, device claims, patient risk, regulatory expectations, and the broader clinical landscape.
Regulatory Requirements Under the IVDR
Performance evaluation requirements are defined primarily in:
- Regulation (EU) 2017/746 (IVDR)
- Annex XIII – Performance Evaluation, Performance Studies, and Performance Follow-up
- Annex II – Technical Documentation
- Annex III – Post-Market Surveillance Documentation
- MDCG guidance documents
- MEDDEV legacy guidance (where applicable)
Manufacturers must establish and maintain:
- A Performance Evaluation Plan (PEP)
- A Performance Evaluation Report (PER)
- A Performance Evaluation Assessment Report (prepared by the Notified Body where applicable)
- A Post-Market Performance Follow-up (PMPF) Plan
- A PMPF Evaluation Report
Performance evaluation is not a one-time activity. It is an ongoing process that continues throughout the device lifecycle.
Components Required in a Performance Evaluation
According to Annex XIII, performance evaluation consists of three pillars.
Scientific Validity
Scientific validity demonstrates that the analyte is associated with a particular clinical condition or physiological state.
Evidence may include:
- Peer-reviewed literature
- Clinical practice guidelines
- Consensus statements
- Professional society recommendations
- Textbooks
- Disease registries
- Public databases
Evidence may include:
- Is the biomarker clinically relevant?
- Is the biomarker recognized by experts?
- Does current medical practice support its use?
Analytical Performance
Analytical performance demonstrates that the device accurately measures the analyte.
Typical studies include:
- Accuracy
- Precision
- Repeatability
- Reproducibility
- Sensitivity
- Specificity
- Limit of Detection (LoD)
- Limit of Quantitation (LoQ)
- Measuring range
- Linearity
- Carryover
- Hook effect
- Interference
- Cross-reactivity
- Stability
- Specimen equivalency
Clinical Performance
Clinical performance demonstrates that the test results are clinically meaningful in the intended patient population.
Evidence may include:
- Clinical performance studies
- Published clinical literature
- Method comparison studies
- Clinical concordance studies
- Retrospective analyses
- Prospective clinical trials
- Real-world evidence
Performance measures often include:
- Clinical sensitivity
- Clinical specificity
- Positive predictive value (PPV)
- Negative predictive value (NPV)
- ROC analysis
- Agreement statistics
- Diagnostic accuracy
The Performance Evaluation Process
Although each device differs, most PERs follow a structured, risk-based process.
Step 1. Define the Intended Purpose
Everything begins with the intended purpose.
This includes:
- Intended use
- Intended user
- Target population
- Specimen type
- Testing environment
- Clinical indication
- Target analyte
Step 2. Develop the Performance Evaluation Plan (PEP)
The PEP defines:
- Evaluation objectives
- Search strategy
- Acceptance criteria
- Data sources
- Study selection methods
- Statistical considerations
- Evidence appraisal methodology
Step 3. Conduct Scientific Literature Review
Manufacturers identify and evaluate:
- Clinical guidelines
- Systematic reviews
- Meta-analyses
- Original research
- Regulatory documents
- State-of-the-art publications
Literature searches should be systematic, reproducible, and well documented.
Step 4. Collect Analytical Performance Data
Manufacturers compile analytical validation studies from:
- Internal verification studies
- Design validation
- External laboratories
- Published evidence
- Reference materials
Step 5. Collect Clinical Performance Evidence
Clinical evidence may come from:
- Manufacturer-sponsored studies
- Published literature
- Clinical registries
- External collaborators
- Comparator studies
- Real-world clinical data
Step 6. Evaluate the Evidence
Each study should be assessed for:
- Scientific quality
- Relevance
- Bias
- Statistical robustness
- Applicability to intended purpose
Evidence is synthesized rather than simply summarized.
Step 7. Perform Benefit-Risk Assessment
Manufacturers evaluate whether:
- Benefits outweigh residual risks
- Performance supports intended use
- Any limitations are acceptable
Step 8. Prepare the Performance Evaluation Report
The PER integrates all available evidence into a single regulatory document.
Step 9. Maintain Through Post-Market Performance Follow-up
Manufacturers continually update the PER using:
- PMPF studies
- Vigilance data
- Complaint investigations
- Literature surveillance
- Trend analysis
- Customer feedback
Documents That Support the PER
A Performance Evaluation Report is supported by a network of technical and quality documents, including:
Core Performance Evaluation Documents
- Performance Evaluation Plan (PEP)
- Performance Evaluation Report (PER)
- Post-Market Performance Follow-up (PMPF) Plan
- PMPF Evaluation Report
Technical Documentation
- Intended Purpose
- Risk Management File
- Usability Engineering File
- Software Documentation (if applicable)
- Design Verification Reports
- Design Validation Reports
- Analytical Validation Reports
- Clinical Performance Study Reports
- Stability Studies
- Labeling
- Instructions for Use (IFU)
Literature and Evidence Documents
- Systematic literature review
- Scientific validity report
- State-of-the-art review
- Clinical guidelines
- Published journal articles
- Consensus statements
Post-Market Documentation
- Post-Market Surveillance (PMS) Plan
- PMS Report or Periodic Safety Update Report (PSUR)
- Vigilance reports
- Trend reports
- Customer complaints
- Corrective and preventive actions (CAPA)
Typical Structure of a Performance Evaluation Report
Although formats vary, a comprehensive PER typically includes:
- Executive Summary
- Scope and Intended Purpose
- Regulatory Background
- Performance Evaluation Methodology
- Scientific Validity Evaluation
- State of the Art
- Analytical Performance Evaluation
- Clinical Performance Evaluation
- Benefit-Risk Analysis
- Conclusions
- Limitations
- Post-Market Performance Follow-up
- References
- Appendices
Many manufacturers also include evidence matrices, literature appraisal tables, traceability matrices, and study quality assessments.
Best Practices for Developing a High-Quality PER
A strong PER goes beyond compiling studies—it critically evaluates the evidence and demonstrates a clear regulatory rationale.
Best practices include:
- Start with a well-defined intended purpose and ensure all evidence aligns with it.
- Develop and follow a documented Performance Evaluation Plan before collecting evidence.
- Use systematic, reproducible literature searches with transparent inclusion and exclusion criteria.
- Critically appraise study quality rather than simply summarizing publications.
- Integrate scientific validity, analytical performance, and clinical performance into a cohesive narrative.
- Ensure consistency across the PER, risk management documentation, labeling, and Instructions for Use.
- Maintain traceability from each performance claim to supporting evidence.
- Establish a routine process for literature surveillance and PMPF to keep the PER current.
- Review the PER regularly to reflect new scientific knowledge, regulatory guidance, and post-market experience.
Best Practices for Developing a High-Quality PER
Manufacturers often encounter difficulties such as:
- Limited published clinical evidence for novel biomarkers
- Inconsistent scientific literature
- Gaps between analytical and clinical evidence
- Poor traceability between performance claims and supporting data
- Outdated literature searches
- Weak justification of benefit-risk conclusions
- Failure to update the PER after market approval
Early planning and cross-functional collaboration among regulatory, clinical, quality, R&D, and medical writing teams can help address these challenges.
Frequently Asked Questions
Is a Performance Evaluation Report required for every IVDR device?
Yes. Every IVD placed on the European market under the IVDR requires performance evaluation appropriate to its risk classification and intended purpose.
Who prepares the PER?
The report is typically prepared by a multidisciplinary team that may include regulatory affairs professionals, medical writers, clinical scientists, biostatisticians, laboratory experts, quality professionals, and subject matter experts.
How often should a PER be updated?
The PER is a living document. It should be reviewed and updated whenever significant new evidence becomes available and as part of the manufacturer’s post-market surveillance and PMPF activities. The frequency should be risk-based and aligned with the device’s classification and lifecycle.
What is the difference between a Performance Evaluation Plan (PEP) and a Performance Evaluation Report (PER)?
The PEP defines how performance evaluation will be conducted, including objectives, methods, and acceptance criteria. The PER documents the results of the evaluation and provides the conclusions supporting the device’s performance.
Can published literature be used instead of conducting new clinical studies?
In some cases, yes. The IVDR allows manufacturers to leverage relevant published scientific literature when it is sufficient to demonstrate scientific validity and clinical performance. However, literature alone may not be adequate for all devices or claims, particularly for novel technologies or high-risk devices.
What is the relationship between the PER and PMPF?
The PER summarizes all available performance evidence, while Post-Market Performance Follow-up (PMPF) is the ongoing process of collecting additional evidence after commercialization. PMPF findings are incorporated into periodic updates of the PER.
Final Thoughts
The Performance Evaluation Report is far more than a regulatory requirement—it is the scientific foundation that demonstrates an IVD device performs as intended and delivers clinically meaningful results. Under the IVDR, manufacturers must take a lifecycle approach to performance evaluation, integrating scientific validity, analytical performance, clinical performance, and post-market evidence into a continually maintained body of documentation.
Organizations that establish robust evidence generation strategies, maintain systematic literature surveillance, and regularly update their PERs are better positioned for successful Notified Body reviews, faster regulatory submissions, and long-term compliance in an evolving regulatory environment.
